FDA grants orphan drug status for Neurocrine’s NBI-77860 to treat CAH
NBI-77860 is a potent, selective non-peptide CRF receptor antagonist as showed in a range of in vitro/in vivo assays and human clinical trials. Blockade of CRF receptors at
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
Speaking ahead of the eyeforpharma Barcelona 2015 conference, Alberto Grua, CCO at Grünenthalechoed similar industry commitments to putting patient’s needs to the forefront of their decision making, and
A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals